Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group Inc. announced that all resolutions proposed at its 2025 First Extraordinary General Meeting were approved by shareholders. The meeting saw participation from a significant number of shareholders and proxies, representing over half of the company’s voting shares, indicating strong shareholder engagement and support for the company’s strategic decisions.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and distribution of pharmaceutical products. The company is based in Zhuhai, Guangdong Province, China, and is involved in both domestic and international markets.
Average Trading Volume: 860,760
Technical Sentiment Signal: Hold
Current Market Cap: HK$33.01B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.